Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-adjusted ATG plus anti-CD25 antibody for GVHD prophylaxis after haploidentical HSCT
ChiCTR2300069733Phase 2Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD) (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: Acute graft-versus-host disease. Started Mar 2023; status: recruiting.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2300069733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069733.